论文部分内容阅读
目的：比较ＶＰ方案与ＭＶＰ方案对非小细胞肺癌（ＮＳＣＬＣ）的治疗效果。方法：７８例患者分别用ＶＰ（ＶＤＳ＋ＤＤＰ）方案和ＭＶＰ（ＭＭＣ＋ＶＰ）方案治疗。结果：ＶＰ组和ＭＶＰ组有效率分别为４５７％（１９／４２）和４７２％（１７／３６），两者无显著性差异（Ｐ＞００５）。分析诸因素对疗效的影响发现，病期早较病期晚疗效好。生活质量评估Ｋａｒｎｏｆｓｋｙ评分ＶＰ组升高为７１４％，ＭＶＰ组为６９４％，两组无显著性差异（Ｐ＞００５）。骨髓抑制为限制性毒性，白细胞下降分别为６９０％和７８８％，无其他严重毒副反应发生。结论：治疗非小细胞肺癌，选用ＶＰ方案能够获得与ＭＶＰ方案相似的疗效
Objective: To compare the therapeutic effect of VP regimen versus MVP regimen on non-small cell lung cancer (NSCLC). Methods: 78 patients were treated with VP (VDS+DDP) regimen and MVP (MMC+VP) regimen, respectively. Results: The effective rates of VP and MVP groups were 45.7% (19/42) and 47. 2% (17/36), respectively. There was no significant difference between the two groups (P>005). Analysis of the impact of various factors on the efficacy found that the early stage of the disease is better than the disease. The quality of life assessment Karnofsky score in the VP group increased by 71.4%, and the MVP group by 69.4%. There was no significant difference between the two groups (P>0.05). Myelosuppression was a restrictive toxicity, with leukopenia of 69.0% and 78.8%, respectively, and no other serious adverse reactions. Conclusion: For the treatment of non-small cell lung cancer, the VP regimen can achieve similar efficacy to the MVP regimen